NewsBenzingaFilana Therapeutics、シムフィラムに関する新たな前臨床研究のイェール大学研究者による発表を公表 ― シムフィラムがヒト細胞株において結節性硬化症複合体2遺伝子を除去し、細胞変化をモデル化する際の影響を検討 Filana Therapeutics、シムフィラムに関する新たな前臨床研究のイェール大学研究者による発表を公表 ― シムフィラムがヒト細胞株において結節性硬化症複合体2遺伝子を除去し、細胞変化をモデル化する際の影響を検討 Benzinga 2026.10.28 12:06 (GMT+0) Open on Benzinga Other news NRX Pharmaceuticals Q3 EPS $(0.05) Beats $(0.21) Estimate, Sales $1.159M Miss $1.300M Estimate HUYA Q3 Adj. EPS $0.03 Up From $0.02 YoY, Sales $261.441M Up From $237.147M YoY Adam Schiff Slams Corporate Executives Over Unreturned Trump Tariff Money: ‘Companies Got Tariff Refunds, Consumers Got…’ Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL Ford Recalls 60,956 Transit Vehicles Over Body Control Module Software Error That Can Shut Off Trailer Lights, Raising Crash Risk Top Wall Street Forecasters Revamp Energizer Expectations Ahead Of Q4 Earnings
Adam Schiff Slams Corporate Executives Over Unreturned Trump Tariff Money: ‘Companies Got Tariff Refunds, Consumers Got…’
Ionis’ Tryngolza Wins European Commission Approval For Severe Hypertriglyceridemia, First RNA-Targeted Therapy In EU For Adults With Triglycerides ≥880 Mg/dL
Ford Recalls 60,956 Transit Vehicles Over Body Control Module Software Error That Can Shut Off Trailer Lights, Raising Crash Risk